Canchew CBD gum
3 min

Could Cannabidiol Chewing Gum Snap IBS?

3 min
CBDshop Research

A Dutch company is entering formal clinical trials to determine if its CBD-infused chewing gum can help stop the symptoms of irritable bowel syndrome.

Axim Biotechnologies, a Netherlands-based company, has entered clinical trials to test the efficacy of their product – CanChew Plus gum - on forty adults aged 18-65 suffering from irritable bowel syndrome.

Axim already has a CBD-gum on the market. CanChew, which contains 10mg of CBD extracted from industrial hemp, has no health claims attached to it. The new version, containing 50mg and an improved delivery system, is now being tested by the company on the campus of Wageningen University.

The purpose of the trial is to specifically examine whether CBD is effective at minimizing the symptoms of IBS – which include bloating, stomach cramps and pain. Patients will chew up to six pieces a day. Researchers will record pain relief and change in stool frequency. If these trials go well, the company will proceed with additional trials on a pharmaceutical grade product they will market as CanChew Rx specifically for the treatment of IBS in adults.
In news reports about the development as far flung as the Indian (English language) press, the study claims to be the first of its kind to test the relationship between CBD and IBS.

“We are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “IBS is the most common functional gastrointestinal disorder affecting 9-15% of the worldwide population, and it has no sustainable cure.”

The company claims that providing CBD via a continuous delivery method like gum, sustained release of the compound and better bioavailability. It currently has a combination CBD/THC gum on the market in all 50 U.S. states called MedChew Rx undergoing efficacy trials for the treatment of multiple sclerosis.


As of 2013, CBD has been recognized as an important chemical in the therapy for inflammatory bowel diseases (including IBS) at an official level. In 2016, the British Journal of Pharmacology found that their own studies reveal that CBD oil interacts with cannabinoid receptors in the digestive tract, which relieve gastrointestinal distress.

That said, historical records as well as specifically medically oriented documents show that CBD oil has a long tradition in both Eastern and Western medical and homeopathic treatments including for treating irritable bowel syndrome specifically.

Cannabis Belly


The CBD market, long treated as cannabis’ poor cousin cannabinoid compared to THC, may actually be coming into its own as medical treatments with cannabis become more mainstreamed thanks to legalization overall and its culture. This cannabinoid in particular, long unregulated as well as ignored, has now become the focus of governments across the EU.

Like THC, CBD appears to have medical efficacy on conditions presenting chronic pain, inflammation, fatigue and muscle spasms. It is also increasingly used to treat epileptics, particularly child epileptics, with great efficacy. It is still unclear which conditions respond or react better to one or the other. Some patients, particularly with chronic pain and PTSD, swear by one or the other – or both – depending on the situation. Name branded medical cannabis in the United States, for example, is beginning to market CBD as the “non-psychoactive alternative” when patients have to drive, go to work, or handle situations that THC can impair performance on and with.


What this latest trial does indicate very clearly, is that different methods of ingestion are beginning to hit Europe if not targeting large national markets in the U.S., Canada, Australia and other regions where medical delivery and services are being legalized and regulated.

The other delivery method that seems to be gaining in popularity for those who do not want to smoke or vape their cannabinoids is transdermal patches. Several brands have been available, particularly in U.S. markets for several years, and delivering different concentrations of THC and CBD.

The question of how or even if raw bud cannabis will continue to be distributed via health systems is clearly one of the many questions that will float around the legalization debate and issue for some time to come. Questions of both cost and efficacy will be central to the European discussion in particular, as cannabinoids of all kinds enter the mainstream pharma and medical verticals. And while such products may have promise in terms of better delivery results, their work is cut out for them across a backdrop of companies who offer similar and in many cases cost competitive product if not customers who can find similar relief via regular dosages of CBD oil drops delivered quickly under the tongue.

What these new delivery methods and products are clearly counting on is that as the industry becomes more regulated, at least in certain markets, it may begin to be able to compete with the raw plant from a consistency or ease of use perspective.

Band Aid Cannabis


  Marguerite Arnold  

Written by: Marguerite Arnold
With years of writing experience under her belt, Marguerite dedicates her time to exploring the cannabis industry and the developments of the legalisation movement.

      Find out about our writers  

Read more about
CBDshop Research
Search in categories